Prof. Roland Martin MD
Dept of Neuroimmunology and MS Research (nims)
University Hospital Zurich
Zürich, Switzerland

Roland Martin studied medicine in Würzburg, Germany, from 1976-1982, received his MD at the University of Hamburg, and after that pursued post-docs in immunology and virology at the Institute of Virology and Immunobiology in Würzburg (until 1985) and later at the Neuroimmunology Branch (NIB), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) (1989-1991). He trained in neurology at the Department of Neurology, University of Würzburg, until 1988. From 1991-1994 Attending and assistant professor for neurology at the Department of Neurology, University of Tübingen. 1994-1996 Heisenberg Professor of the German Research Society with joint appointment in Tübingen and at NIB, NINDS, NIH. From 1997-2005 section chief (Cellular Immunology Section) and tenured senior investigator at NIB, NINDS, NIH. 2005-2006 ICREA (Catalan Institute for Research and Advanced Studies) Professor at the Multiple Sclerosis Center at University Hospital Vall D’Hebron, Barcelona. From 2006-2011 Director of the Institute for Neuroimmunology and Clinical MS Research at the University Hospital Hamburg Eppendorf. From 2011-2022 full professor for neurology and neuroimmunology at the University of Zurich and head of the MS center at the Neurology Clinic, University Hospital Zurich. Since August 2022 emeritus professor and continuing research at the Institute of Experimental Immunology, University of Zurich, and the Therapeutic Design Unit, Department of Clinical Neurosciences, Karolinska Institute, Stockholm. R. Martin is also a co-founder and currently Chief Scientific Officer of Cellerys, a startup that has been outfounded from the University of Zurich and pursues antigen-specific tolerance induction in a partnership with Novartis. His main research interests are pathomechanisms and cellular immune reactions in multiple sclerosis and neuro-infectious diseases, the identification of target antigens and the development of new treatments for MS.